Avidity Biosciences Inc. (RNA) News
Filter RNA News Items
RNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RNA News Highlights
- RNA's 30 day story count now stands at 3.
- Over the past 13 days, the trend for RNA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest RNA News From Around the Web
Below are the latest news stories about Avidity Biosciences Inc that investors may wish to consider to help them evaluate RNA as an investment opportunity.
Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical OfficerAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Steve Hughes, M.D. as chief medical officer. Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at prominent biopharmaceutical companies. |
Avidity Biosciences to Participate in Upcoming Investor ConferencesAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Avidity management team will be participating at the following conferences: |
Avidity Biosciences (NASDAQ:RNA) investors are sitting on a loss of 25% if they invested a year agoIt's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do both... |
Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ...Investment company Rtw Investments, Lp (Current Portfolio) buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, argenx SE, Macrogenics Inc, sells Quidel Corp, Protagonist Therapeutics Inc, MiMedx Group Inc, , Castle Biosciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Rtw Investments, Lp. |
Avidity Biosciences (NASDAQ:RNA) Shares Gap Down to $24.32Avidity Biosciences, Inc. (NASDAQ:RNA)s share price gapped down before the market opened on Friday . The stock had previously closed at $24.32, but opened at $22.15. Avidity Biosciences shares last traded at $22.71, with a volume of 101 shares changing hands. RNA has been the topic of a number of research analyst reports. Evercore ISI [] |
Avidity Biosciences (RNA) Buy Rating Reaffirmed at Wells Fargo & CompanyWells Fargo & Company restated their buy rating on shares of Avidity Biosciences (NASDAQ:RNA) in a research note issued to investors on Friday morning, TipRanks reports. They currently have a $59.00 price objective on the biotechnology companys stock. A number of other equities analysts also recently commented on the stock. SVB Leerink boosted their target [] |
SVB Leerink Raises Avidity Biosciences (NASDAQ:RNA) Price Target to $53.00Avidity Biosciences (NASDAQ:RNA) had its price objective lifted by SVB Leerink from $36.00 to $53.00 in a report issued on Friday morning, Stock Target Advisor reports. The firm currently has an outperform rating on the biotechnology company’s stock. Other analysts have also recently issued reports about the company. Evercore ISI began coverage on Avidity Biosciences […] |
Avidity Biosciences (NASDAQ:RNA) Shares Up 6.6% After Analyst UpgradeAvidity Biosciences, Inc. (NASDAQ:RNA)’s share price shot up 6.6% during mid-day trading on Monday after SVB Leerink raised their price target on the stock from $36.00 to $53.00. SVB Leerink currently has an outperform rating on the stock. Avidity Biosciences traded as high as $26.02 and last traded at $25.98. 1,505 shares were traded during […] |
Avidity Biosciences (NASDAQ:RNA) Price Target Raised to $53.00Avidity Biosciences (NASDAQ:RNA) had its target price increased by equities researchers at SVB Leerink from $36.00 to $53.00 in a research report issued to clients and investors on Friday, Stock Target Advisor reports. The firm presently has an outperform rating on the biotechnology companys stock. SVB Leerinks target price points to a potential upside of [] |
Wells Fargo & Company Reiterates Buy Rating for Avidity Biosciences (NASDAQ:RNA)Avidity Biosciences (NASDAQ:RNA)s stock had its buy rating reiterated by equities researchers at Wells Fargo & Company in a report issued on Friday, TipRanks reports. They presently have a $59.00 price objective on the biotechnology companys stock. Wells Fargo & Companys target price suggests a potential upside of 142.10% from the companys previous close. Several [] |